The evidence indicates distinct prognostic patterns: biomarkers of inflammation (e.g., TNF-α, IL-6, IL-1β) and neuronal or glial damage (e.g., S100B, GFAP, NSE, NfL) tend to correlate with less favorable outcomes, especially when measured in the acute phase of a stroke. This evidence concerns the gene IL1B and stroke disorder.